Novavax, Inc. (NVAX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 14.40 |
| Open | 14.37 |
| Bid | 12.97 x 2800 |
| Ask | 13.02 x 600 |
| Day's Range | 12.95 - 14.38 |
| 52 Week Range | 3.53 - 15.00 |
| Volume | |
| Avg. Volume | 12,763,143 |
| Market Cap | 1.916B |
| Beta (5Y Monthly) | 1.62 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Novavax to Participate in BofA Securities 2024 Health Care Conference
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the BofA Securities 2024 Health Care Conference.
- PR Newswire
Novavax Reports First Quarter 2024 Financial Results and Operational Highlights
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced its financial results and operational highlights for the first quarter ended March 31, 2024.
- PR Newswire
Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, has entered into a co-exclusive licensing agreement with Sanofi (Nasdaq: SNY).
© 2024 Yahoo. All rights reserved.